Clinical Trial Update: An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 efficacy and safety study of three fixed doses of JNJ-37822681 in schizophrenia, sponsored by Johnson & Johnson,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• JNJ-37822681

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED